Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Oral Antidiabetic Drugs Market Set To Climb From $71.42 Billion In 2026 To $92.64 Billion By 2030
The oral antidiabetic drugs market size has demonstrated strong growth in recent years. This market is projected to expand from $66.73 billion in 2025 to $71.42 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.0%. The expansion observed in the historic period can be attributed to several factors, including the limited availability of oral antidiabetic drug classes, a continued reliance on conventional biguanides and sulfonylureas, the increasing incidence of type 2 diabetes, growing hospital and pharmacy distribution networks, and rising awareness of diabetes management.
The oral antidiabetic drugs market is projected to experience substantial expansion in the coming years, reaching a valuation of $92.64 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.7%. This anticipated growth during the forecast period is attributable to several factors, including the emergence of new DPP-4 and SGLT2 inhibitors, the broadening availability of combination therapies, a greater embrace of personalized medicine strategies, the rise of online pharmacies and telemedicine platforms, and increased governmental efforts in diabetes management. Key trends identified for this period encompass the growing incidence of type 2 diabetes, a heightened uptake of combined oral antidiabetic medications, the expansion of both online and physical retail pharmacy outlets, an intensified focus on individualized diabetes management, and improved awareness and educational initiatives concerning diabetes care.
Get A Free Sample Report With In-Depth Market Insights:
Oral Antidiabetic Drugs Market Demand Drivers: What’s Powering Industry Growth?
The projected growth of the oral antidiabetic drugs market is expected to be propelled by the increasing prevalence of type 2 diabetes. Type 2 diabetes describes a chronic condition where the body either develops resistance to insulin or fails to produce sufficient amounts to maintain normal glucose levels. The rise in type 2 diabetes is attributed to increasing obesity rates, as excessive body fat leads to insulin resistance and impaired glucose regulation. Oral antidiabetic drugs assist in managing type 2 diabetes by enhancing insulin sensitivity, boosting insulin secretion, or reducing glucose production and absorption, thereby helping to maintain optimal blood sugar levels. For instance, in March 2025, the Office for Health Improvement and Disparities, a UK-based government agency, reported that the prevalence of type 2 diabetes in adults aged 17+ in England increased to 7.0%, up from 6.8% in March 2023. Consequently, the rising incidence of type 2 diabetes is driving the expansion of the oral antidiabetic drugs market.
Oral Antidiabetic Drugs Market Segment Breakdown: Which Categories Lead On Revenue?
The oral antidiabetic drugs market covered in this report is segmented –
1) By Drug Class: Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Sodium Glucose Transport Protein -2 Inhibitors, Sulfonylureas, Thiazolidinediones, Megalitinides, Alpha Glucosidase Inhibitors, Other Drug Classes
2) By Route Of Administration: Oral, Sublingual, Buccal
3) By Therapeutic Area: Type 2 Diabetes, Gestational Diabetes, Type 1 Diabetes
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Channels
5) By End User: Hospitals, Pharmact Store, Drug Store, Diabetes Treatment Centers, Other End Users
Subsegments:
1) By Biguanides: Metformin Hydrochloride, Metformin Extended Release, Combination Products
2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin
3) By Sodium Glucose Transport Protein-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin
4) By Sulfonylureas: Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide
5) By Thiazolidinediones: Pioglitazone, Rosiglitazone
6) By Meglitinides: Repaglinide, Nateglinide
7) By Alpha Glucosidase Inhibitors: Acarbose, Miglitol, Voglibose
8) By Other Drug Classes: Bromocriptine, Colesevelam
Oral Antidiabetic Drugs Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies in the oral antidiabetic drugs market are concentrating on clinical trials to develop more effective and safer treatment options, broaden their product portfolios, and achieve regulatory approvals for next-generation therapies. Clinical trials are structured research studies conducted with human participants to assess the safety, effectiveness, and potential side effects of new medical treatments, drugs, or interventions. For instance, in April 2025, Eli Lilly and Company, a US-based pharmaceutical company, launched Orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist designed to simplify diabetes management following a successful phase 3 trial. This oral therapy seeks to offer comparable efficacy and safety to injectable options while simultaneously improving patient adherence. In clinical trials, orforglipron decreased HbA1c (a measure of blood sugar control) by an average of 1.3% to 1.6% across various doses over 40 weeks.
Oral Antidiabetic Drugs Market Leading Players And Competitive Positioning
Major companies operating in the oral antidiabetic drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, C.H. Boehringer Sohn AG & Co. KG, Viatris Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Cipla Limited
View The Full Oral Antidiabetic Drugs Market Report:
Oral Antidiabetic Drugs Market Geographic Spread And Regional Opportunities
North America was the largest region in the oral antidiabetic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral antidiabetic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
